Klin Farmakol Farm. 2004;18(4):218-222

Antidepresiva s duálním působením - účinnost a indikace

Klára Látalová, doc. MUDr. Vladimír Pidrman Ph.D
Psychiatrická klinika FN a LF UP, Olomouc

Keywords: depression, serotonine, dopamine, norepinephrine.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Látalová K, Pidrman V. Antidepresiva s duálním působením - účinnost a indikace. Klin Farmakol Farm. 2004;18(4):218-222.

Článek stručně předkládá základní charakteristiky venlafaxinu, milnacipranu a bupropionu, léčiv, která jsou představiteli moderních antidepresiv s duálním působením na aktivitu neurotransmiterových systémů. Tato farmaka představují tzv. čtvrtou generaci antidepresiv. Ovlivňují zároveň noradrenalinový a serotoninový, resp. dopaminový systém (SNRI - inhibitory zpětného vychytávání serotoninu a noradrenalinu, DNRI - inhibitory zpětného vychytávání dopaminu a noradrenalinu) a jsou spojována s vysokou účinností, schopností udržet dlouhodobou remisi při dobré snášenlivosti a bezpečnosti z hlediska předávkování. Zabývá se jejich postavením mezi ostatními skupinami antidepresiv, zejména ve vztahu ke klasickým tricyklickým antidepresivům (TCA) a široce používaným selektivním inhibitorům zpětného vychytávání serotoninu (SSRI).

DUAL-ACTION ANTIDEPRESSANTS - EFFICACY AND INDICATION

This article briefly presents the main features of venlafaxine, milnacipran and bupropion as representatives of modern dual-action antidepressants. These substances are so called fourth generation antidepressants with simultaneous effects on norepinephrine and serotonin or dopamine systems (SNRI - serotonin and norepinephrine reuptake inhibitors, DNRI - dopamine and norepinephrine reuptake inhibitors). These antidepressants are associated with high efficacy, an ability to maintain long-term remission while being well tolerated and safe in case of overdosing. The article deals with their positions among other antidepressants, particularly in relation to classical tricyclic antidepressants (TCA) and widely used selective serotonin reuptake inhibitors (SSRI).

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ascher JA, Cole JO, et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiat., 1995; 56: 395-401.
    2. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychophramacol, 1996; 11(Suppl.4): 10-14. Go to original source... Go to PubMed...
    3. Braunwald E. Harisson´s principles of internal medicine. McGraw-Hill Book Comp., New York, 1998: 2918 s.
    4. Clerc G, et al. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenalin inhibitor. Int Clin Psychopharmacol, 2001; 16: 1-7. Go to original source... Go to PubMed...
    5. Cozza KL, Armstrong SC. The cytochrome P450 system. Drug interaction principles for medical practice. American Psychiatric Publishing, Inc., Washington, DC, 2001: 262 s.
    6. Cunningham LA. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Ann Clin Psychiatry. 1994; 9(3): 157-164. Go to original source...
    7. Češková E, Kašpárek T. Polyfarmakoterapie u depresivní poruchy. Čes. a slov. Psychiatrie 2002; 58: 19-36.
    8. Entsuah R, a kol. Venlafaxine and SSRIs: Pooled Remission Analysis (Megaanalysis of 31 studies of more 7000 Patients). Abstract book of ANCP 2002, Puerto Rico.
    9. Fava M. Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiat., 2001; 62 (Suppl. 18): 4-11.
    10. Goodyer IM. Unipolar depression. Oxford University Press, New York, 2003: 212.
    11. Henn F, Sartorius N, Helmchen H, Lauter H. Contemporary psychiatry. Springer, Berlin, 2001: 2258s. Go to original source...
    12. Jacobson SA, Pies RW, Greenblatt DJ. Handbook of geriatric psychopharmacology. American Psychiatric Publishing, Inc., Washingon, DC, 2002: 496s.
    13. Kasper S, Pletan Y, Solies A, Tournox A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with a major depression: a summary of clinical trials. Int Clin Psychopharmacol, 1996; 11,(4): 35-39. Go to original source... Go to PubMed...
    14. Marangell LB. Switching antidepressants for treatment-resistant major depression. J. Clin. Psychiat., 62, 2001; suppl. 18): 2-7.
    15. Montgomery SA, et al. Efficacy and tolerability of milnacipran: an overview. Int. Clin. Psychopharmacol., 1996; 6(suppl.4): 47-51. Go to original source... Go to PubMed...
    16. Montgomery SA, Schatzberg AF, et al. Pharmacotherapy of depression and mixed states in bipolar disorder. Journ. Aff. Disorders, 59, 2000; (suppl 3): 39-56. Go to original source... Go to PubMed...
    17. Moret C, Briley M. In vivo study of monoamines neurotransmission by milnacipran. Brain Research Association Abstracts, 1996; 13: 35.
    18. Moret C, Charveron M, Finberg JPM, Briley M. Biochemical profile of milnacipran, a potential fourth generation antidepressant drug. Neuropharmacology, 1985; 24: 1211-1219. Go to original source... Go to PubMed...
    19. Pidrman V. Deprese a kardiovaskulární onemocnění. Maxdorf, Praha, 2. rozšířené vydání, 2002: 48 s.
    20. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, Professional Communications, Inc.,1996: 256s.
    21. Preskorn SH. Outpatient management of depression. Professional Communication, Inc., Caddo, 1999: 256.
    22. Product monograph bupropion hydrochloride sustained release tablets. Mississauga, Glaxo Wellcome Inc., 1998: 35.
    23. Puech A, Montgomery SA, Prost JF, Briley M. Milnacipran, a new serotonin and noradrenalin reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol, 1997; 12: 99-108. Go to original source... Go to PubMed...
    24. Raboch J, Zvolský P, a kol. Psychiatrie. Praha, Galén a Univerzita Karlova, Karolinum, 2001: 622s.
    25. Rouet RH, et al. Comparative in vivo and in vitro study of the cardiac effect of milnacipran and imipramine. Fundam. Clin. Pharmacol., 1989; 3: 237-244. Go to original source... Go to PubMed...
    26. Rouillon F, et al. Milnacipran efficacy in the prevention of recurent depression: a 12 month placebo - controlled study. Int. Clin. Psychopharmacol., 2000; 15: 133-40. Go to original source... Go to PubMed...
    27. Schatzberg AF, DeBattista Ch, Overman GP, Ereshevsky L. The 1998 black book of psychotropic dosing and monitoring. New York, MBL Communications, Inc., 1998: 40s.
    28. Settle EC. Bupropion sustained release: side effect profile. J. Clin. Psychiat., 1999; 59 (Suppl. 4): 32-36.
    29. Settle EC, Stahl SM, et al. Safety profile of sustained release bupropion in depression: results of theree clinical trials. Clin. Therap., 1999; 3: 454-464. Go to original source... Go to PubMed...
    30. Schaltberg AF, Cole JO, DeBatista C. Manual of clinical psychopharmacology. American Psychiatric Publishing, Inc. Washington, DC, 2003: 700s.
    31. Shiloh R, Nutt D, Weizman A. Atlas of psychotropic pharmacotherapy, Martin Dunitz, London, 2000: 235s.
    32. Simon GE, a kol. WHO Bulletin 2000; 78: 439-445. Go to original source...
    33. Solai LK, Mulsant BH, Pollock BG. Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drug Aging, 2001; 18 (5): 355-368. Go to original source... Go to PubMed...
    34. Spar EJ, La Rue A. Concise guide to geriatric psychiatry. American Psychiatric Publishing, Inc., Washington, DC, 2002; 372s.
    35. Spencer AM, Wilde MI. Milnacipran, a review of its use in depression. Drugs, 1998; 56(3): 405-427. Go to original source... Go to PubMed...
    36. Spier SA. Use of bupropion with SSRIs and venlafaxine. Depress Anxiety,1998; 7: 73-75. Go to original source... Go to PubMed...
    37. Stahl SM. Essential psychopharmacology. Neurocsietntific basis and practical applications. Cambridge University Press, Cambridge, 2002: 602.
    38. Stahl SM. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge University Press, 1996: 148.
    39. Stahl SM. Essential psychopharmacology of depression and bipolar disorder. New York, Cambridge University Press, 2000: 176.
    40. Stahl SM. Psychopharmacology of antidepressants. London, Martin Dunitz, Ltd, 1998: 114.
    41. Švestka J. Bupropion - dopaminergní a noradrenergní antidepresivum. Psychiatrie, 5, 2001; 3: 196-209.
    42. Švestka J. Vývoj antidepresiv od prvé k páté gereraci. Praha: Psychiatrické centrum, 1994; Zprávy č. 133, 96s.
    43. Švestka J. SNRI - příklad venlafaxinu. Psychiatrie 1997; 3-4: 135-38.
    44. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001; 178: 234-41. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.